ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 180 filers reported holding ASCENDIS PHARMA A/S in Q1 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $552,289 | +48.2% | 5,898 | +41.3% | 0.26% | +50.6% |
| Q2 2023 | $372,619 | -52.6% | 4,175 | -43.1% | 0.17% | -73.5% |
| Q1 2023 | $786,780 | -12.2% | 7,338 | 0.0% | 0.64% | +20.5% |
| Q4 2022 | $896,190 | -11.3% | 7,338 | -25.0% | 0.53% | -7.8% |
| Q3 2022 | $1,010,000 | +46.0% | 9,780 | +31.4% | 0.58% | +38.0% |
| Q2 2022 | $692,000 | -24.6% | 7,442 | -4.8% | 0.42% | -28.4% |
| Q1 2022 | $918,000 | -20.1% | 7,821 | -8.4% | 0.58% | -36.2% |
| Q4 2021 | $1,149,000 | -26.2% | 8,541 | -12.6% | 0.92% | -11.2% |
| Q3 2021 | $1,557,000 | +95.4% | 9,769 | +61.2% | 1.03% | +82.3% |
| Q2 2021 | $797,000 | +12.4% | 6,060 | +10.1% | 0.56% | +7.2% |
| Q1 2021 | $709,000 | -10.1% | 5,505 | +16.4% | 0.53% | +4.6% |
| Q4 2020 | $789,000 | +54.7% | 4,731 | +43.1% | 0.50% | +35.5% |
| Q3 2020 | $510,000 | +19.2% | 3,307 | +14.3% | 0.37% | +5.1% |
| Q2 2020 | $428,000 | – | 2,893 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |